Abstract
Aspirin is the most widely employed antithrombotic agent in use today and has a proven role in the prevention and acute management of atherosclerosis-associated arterial thrombotic events. More recently developed antiplatelet agents have been found to have specific prophylactic roles associated with percutaneous coronary intervention and other clinical settings. This article outlines pharmacologic considerations and current clinical knowledge relevant to the use of aspirin, ticlopidine, clopidogrel, and the GPIIbIIIa antagonists in the management of thrombotic disorders.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 1231-1249 |
| Number of pages | 19 |
| Journal | Hematology/Oncology Clinics of North America |
| Volume | 12 |
| Issue number | 6 |
| DOIs | |
| State | Published - 1998 |
| Externally published | Yes |
Fingerprint
ASJC Scopus subject areas
- Oncology
- Hematology
Cite this
Antiplatelet therapy : Aspirin, ticlopidine/clopidogrel, and anti- integrin agents. / Calverley, David; Roth, G. J.
In: Hematology/Oncology Clinics of North America, Vol. 12, No. 6, 1998, p. 1231-1249.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Antiplatelet therapy
T2 - Aspirin, ticlopidine/clopidogrel, and anti- integrin agents
AU - Calverley, David
AU - Roth, G. J.
PY - 1998
Y1 - 1998
N2 - Aspirin is the most widely employed antithrombotic agent in use today and has a proven role in the prevention and acute management of atherosclerosis-associated arterial thrombotic events. More recently developed antiplatelet agents have been found to have specific prophylactic roles associated with percutaneous coronary intervention and other clinical settings. This article outlines pharmacologic considerations and current clinical knowledge relevant to the use of aspirin, ticlopidine, clopidogrel, and the GPIIbIIIa antagonists in the management of thrombotic disorders.
AB - Aspirin is the most widely employed antithrombotic agent in use today and has a proven role in the prevention and acute management of atherosclerosis-associated arterial thrombotic events. More recently developed antiplatelet agents have been found to have specific prophylactic roles associated with percutaneous coronary intervention and other clinical settings. This article outlines pharmacologic considerations and current clinical knowledge relevant to the use of aspirin, ticlopidine, clopidogrel, and the GPIIbIIIa antagonists in the management of thrombotic disorders.
UR - http://www.scopus.com/inward/record.url?scp=0032443790&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0032443790&partnerID=8YFLogxK
U2 - 10.1016/S0889-8588(05)70051-4
DO - 10.1016/S0889-8588(05)70051-4
M3 - Article
C2 - 9922934
AN - SCOPUS:0032443790
VL - 12
SP - 1231
EP - 1249
JO - Hematology/Oncology Clinics of North America
JF - Hematology/Oncology Clinics of North America
SN - 0889-8588
IS - 6
ER -